title: Radioimmunotherapy for non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  To describe the rationale for radioimmunotherapy as a treatment of non-Hodgkin's lymphoma. To present the similarities and differences in the two radioimmunotherapies and the nursing implications in caring for patients receiving these agents.
  
  
  METHODS
  Published literature and review of published clinical trials.
  
  
  CONCLUSIONS
  Radiolabeled monoclonal antibodies bind to specific antigens and provide a means of targeting tumor cells with cytotoxic radioactivity. The infusion of radiolabeled monoclonal antibodies requires an understanding of antibody therapy, radiation therapy, and principles of time, distance, and shielding.
  
  
  CONCLUSIONS
  As the use of radioimmunotherapy grows, nurses must be aware of the background for, logistics of, and follow-up required for patients receiving this form of radiation treatment.
authors.affiliation: Department of Radiation Oncology, Baptist Hospital, Pensacola, FL 32501, USA. pat.liebenguth@bhcpns.org
authors.forename: Pat
authors.initials: P
authors.lastname: Liebenguth
authors.forename: Susan
authors.initials: S
authors.lastname: Vogt Temple
mesh_terms: D000359:Aftercare / Q000379:methods; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005544:Forecasting; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000451:nursing / Q000532:radiotherapy*; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000379:methods*; D018579:Patient Selection; D018787:Radiation Oncology / Q000379:methods; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods* / Q000451:nursing; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab; C422802:ibritumomab tiuxetan; C119496:tositumomab I-131